Immix Biopharma, Inc. — Director's Dealing 2021

Dec 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immix Biopharma, Inc. (IMMX)
CIK: 0001873835
Period of Report: 2021-12-20

Reporting Person: Ng Carey (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-20	Common Stock	C	1000221	$0.85	Acquired	1000221	Indirect
2021-12-20	Common Stock	P	25000	$5.00	Acquired	1025221	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-20	Convertible Note	$0.85	C		Disposed		Common stock (1000221)	Indirect

Footnotes

F1: Carey Ng is the Managing Director of Mesa Verde Venture Partners III, LP and in such capacity has the right to vote and dispose of the securities held by such entity.

F2: On October 30, 2019, the Registrant issued Mesa Verde Venture Partners III, LP a note in the amount of $750,000 which is payable upon request of the majority holders of like tenure notes on or after October 30, 2021. Pursuant to the terms of the note, because the Registrant sold equity securities in its initial public offering resulting in proceeds of at least $10 million, the note automatically converted into shares of the Registrant's common stock.